Cagrilintide Peptide API

Key Specifications

Amino Acid Sequence:
{Eicosanedioic acid-γ-Glu}-Lys-Cys-Asn-Thr-Ala-Thr-Cys-Ala-Thr-Gln-Arg-Leu-Ala-Glu-Phe-Leu-Arg-His-Ser-Ser-Asn-Asn-Phe-Gly-Pro-Ile-Leu-Pro-Pro-Thr-Asn-Val-Gly-Ser-Asn-Thr-Pro-NH₂ (Disulfide bridge: Cys3-Cys8)

Mechanism of Action

Cagrilintide is a potent and selective amylin receptor agonist. Amylin is a pancreatic β-cell hormone that works in conjunction with insulin to regulate glucose homeostasis and energy balance.

Key pharmacological effects include:

• Appetite suppression – acts on the hypothalamus and hedonic brain regions to reduce food intake

• Increased satiety – promotes feelings of fullness, reducing caloric consumption

• Delayed gastric emptying – slows nutrient absorption

• Weight-independent glucose lowering – complementary to GLP-1 mechanisms

• • • • • • •  

    • • Clinical Development

        Cagrilintide is the most advanced long-acting amylin analog in clinical development, with an extensive Phase 3 program underway.

      • Monotherapy (REDEFINE 1)

        
        

        
        

        Endpoint	Cagrilintide	Placebo
        Mean weight loss at 68 weeks	11.8%	2.3%
        ≥15% weight loss	31.6%	4.7%

         

         

        Combination with Semaglutide (CagriSema)

        REDEFINE 1 (obesity):

        • 22.7% weight loss at 68 weeks (vs. 2.3% placebo)

        • 91.9% achieved ≥5% weight loss

        • ~54% achieved non-obese status (BMI <30)

        REDEFINE 2 (obesity + T2DM):

        • 15.7% weight loss at 68 weeks (vs. 3.1% placebo)

        • 89.7% achieved ≥5% weight loss

        Regulatory Status

        
        

        
        

        Item	Status
        FDA Submission (CagriSema)	December 2025; review expected 2026
        Highest Phase	Phase 3
        Indications	Obesity, T2DM

         

        Safety Profile

        The most common adverse events are gastrointestinal in nature, typically mild to moderate and diminishing over time.

        
        

        
        

        Adverse Event	Cagrilintide	CagriSema
        Nausea	20-47%	~55%
        Constipation	Not reported	~31%
        Vomiting	Not reported	~26%
        Discontinuation due to nausea	1.0%	-

         

        Why Choose Our Cagrilintide API？

        • High purity (≥99% by HPLC)

        • cGMP manufacturing

        • COA, stability data, DMF available

        • 24-month shelf life

        • Regulatory filing support

        • Reliable supply chain

        ---

        Applications

        • Preclinical and clinical research for obesity, overweight, and type 2 diabetes

        • Combination therapy development (CagriSema)

        • Generic API development

        • Analytical reference standard

        • Clinical trial material supply

        Market & Development Highlights

        
        

        
        

        Item	Status
        Originator	Novo Nordisk
        Mechanism	Amylin analog (long-acting)
        Administration	Once-weekly
        Lead Indication	Obesity, T2DM
        Highest Phase	Phase 3
        DMF Status	Available upon request

        ---

        Packaging & Storage

        
        

        
        

        Parameter	Condition
        Storage	-20°C ± 5°C, dry, protected from light
        Shelf Life	24 months
        Packaging	Sealed pharmaceutical-grade containers
        Shipping	Temperature-controlled

        ---

        Documentation Available

        • Certificate of Analysis (COA)

        • Stability study data

        • GMP statement

        • DMF (available upon request)

        • Regulatory filing support

        ---

        Contact Us

        For pricing, DMF status, sample requests, or technical inquiries regarding Cagrilintide API or CagriSema combination development, please contact our sales team.